400 related articles for article (PubMed ID: 16144928)
1. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles FJ; Faderl S; Kantarjian HM
Blood; 2001 Sep; 98(6):1708-13. PubMed ID: 11535501
[TBL] [Abstract][Full Text] [Related]
6. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
7. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
[TBL] [Abstract][Full Text] [Related]
8. Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia.
Cervantes F; Camós M; Boqué C; Besses C; Alcalá A; Sureda A
Haematologica; 2004 Jul; 89(7):870-1. PubMed ID: 15257944
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
Brennan BJ; Xu ZX; Grippo JF
Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
[TBL] [Abstract][Full Text] [Related]
11. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
Bukowski RM; Tendler C; Cutler D; Rose E; Laughlin MM; Statkevich P
Cancer; 2002 Jul; 95(2):389-96. PubMed ID: 12124839
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson J; Gurney H; Selby P; Figlin R; Negrier S; Ernst S; Siebels M; Ginsberg M; Rittweger K; Hooftman L
Ann Oncol; 2002 Nov; 13(11):1799-805. PubMed ID: 12419754
[TBL] [Abstract][Full Text] [Related]
13. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).
Bressler B; Wang K; Grippo JF; Heathcote EJ
Br J Clin Pharmacol; 2009 Mar; 67(3):280-7. PubMed ID: 19523011
[TBL] [Abstract][Full Text] [Related]
18. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
[TBL] [Abstract][Full Text] [Related]
20. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
